Merieux Equity Partners

AcuSurgical has successfully completed its first clinical study with the world's first dual-instrument ophthalmic surgical system, Luca™. Conducted at Ghent University Hospital in Belgium, this milestone represents a significant advancement in retinal microsurgery. 👁️   The Luca™ robot offers greater precision, achieving an accuracy of 10μm (compared to the 100μm normally achieved by a surgeon's hand), representing a major step forward since allowing precise surgery on the retina that is c.300μm width. Under the leadership of Dr. Fanny Nerinckx, seven high-precision robotic surgeries have been seamlessly integrated into the operating room workflow. This success paves the way for larger trials, including full vitreoretinal surgery and subretinal gene therapy.   At Merieux Equity Partners, we are proud to support AcuSurgical since 2021, through our OMX Europe Venture fund. We remain committed to their mission of revolutionizing ophtalmic surgery with innovative solutions, improving the lives of millions of people suffering from retinal diseases such as AMD, diabetic retinopathy, and macular holes. 🚀   #Innovation #RoboticSurgery #Ophthalmology #RetinalHealth

AcuSurgical has successfully completed its first clinical study with the world's first dual-instrument ophthalmic surgical system, Luca™. Conducted at Ghent University Hospital in Belgium, this milestone represents a significant advancement in retinal microsurgery. 👁️   The Luca™ robot offers greater precision, achieving an accuracy of 10μm (compared to the 100μm normally achieved by a surgeon's hand), representing a major step forward since allowing precise surgery on the retina that is c.300μm width. Under the leadership of Dr. Fanny Nerinckx, seven high-precision robotic surgeries have been seamlessly integrated into the operating room workflow. This success paves the way for larger trials, including full vitreoretinal surgery and subretinal gene therapy.   At Merieux Equity Partners, we are proud to support AcuSurgical since 2021, through our OMX Europe Venture fund. We remain committed to their mission of revolutionizing ophtalmic surgery with innovative solutions, improving the lives of millions of people suffering from retinal diseases such as AMD, diabetic retinopathy, and macular holes. 🚀   #Innovation #RoboticSurgery #Ophthalmology #RetinalHealth

Nominations Announcement 🚀 We are thrilled to announce two strategic promotions within Merieux Equity Partners Buyout team: 👏 Jean-François Billet, previously Managing Partner, has been appointed Managing Partner and Head of Buyout, a newly created role following the growth of the Buyout team. Jean-François will be responsible for structuring the development of the activity as well as leading the team. 👏 Theodor Wuppermann has been promoted to Partner. Since joining us in May 2023, Theodor has made significant contributions, particularly with our recent investments in Labquality, based in Finland, and InnoSyn B.V., based in the Netherlands. We wish them the best in their new roles! #Promotion #Nomination #Investment #MxEP #Buyout

AstriVax, a pioneer in innovative vaccine technology, has entered the clinical phase with its new vaccine platform.   The first participants in the SAFYR Phase I clinical trial have been dosed, marking a critical step in testing the safety and efficacy of their prophylactic vaccines for yellow fever and rabies. With their innovative technology, AstriVax vaccines are easy to produce, have limited cold chain requirements, and promise to transform the fight against viral infections. Merieux Equity Partners is proud to support AstriVax on their development since their inception via our OMX Europe fund.   Congratulations to the AstriVax team - we look forward to the next steps in their journey towards innovative health solutions for chronic infections such as Hepatitis B.   🔗 https://lnkd.in/d5ADh5R6   #Innovation #Healthcare #Vaccine

Merieux Equity Partners recherche un(e) Assistant(e) en alternance à Lyon. Ce poste polyvalent couvre les domaines de la comptabilité, du juridique, de la conformité et de l'office management, permettant à l'étudiant d'acquérir une expérience au sein d'un back office dynamique.

🌿 Bravo à Plantex , l'une des participations du fonds Mérieux Participations 3, pour cette initiative renforçant ainsi son engagement envers l'éco-responsabilité.   En collaborant avec des apiculteurs locaux pour intégrer des ruches dans leurs installations, Plantex contribue à la préservation de la biodiversité et à l'adoption de pratiques durables.   Cette initiative s'aligne parfaitement avec les valeurs d'investissement responsable de Merieux Equity Partners.   #RSE #Investissement #Sustainability #Durabilité

We are delighted to announce that Labquality, supported by Merieux Equity Partners with its fund Mérieux Participations 4, has acquired Swedish QAdvis AB, strengthening its regulatory affairs and quality management capabilities in the healthcare technology sector ! 🤝   With their strong foothold in the Swedish market and extensive expertise in medical device software, this acquisition fits with Labquality's international growth strategy and consolidates Labquality's position as an expert service provider in the healthcare technology sector.   Mérieux Participations 4 primarily invests in companies with high organic growth and in buy-and-build platforms, exemplified perfectly by Labquality.   Read the press release here ➡ https://lnkd.in/gWWCsKdH   #Labquality #HealthTech #RegulatoryAffairs #Acquisition #Innovation

Merieux Equity Partners will be present at the SuperReturn International in InterContinental Berlin from June 4 to 7.   Merieux Equity Partners is one of the leading Healthcare European Investors, covering both buyout and innovation capital. Our sector expertise has recently been recognized by members of the healthcare ecosystem in the Real Deals Healthcare Report 2024.   Thierry CHIGNON and Jean Chatillon look forward to meeting you in Berlin and discussing about investments in the #healthcare sector.   https://lnkd.in/e6pggn2y   #LPs #Investment #SuperReturn

Many thanks to all our International investors (Institutional and Family Offices) and portfolio CEOs who took part in Merieux Equity Partners’ Buy Out AGM in Paris yesterday to discuss our funds, investments and plans for the year ahead.   #privateequity #venturecapital #healthcare #investment

📣 Merieux Equity Partners will be taking part on Thursday, May 23rd, 2024 in the Bio Investment Convention (BIC) organized by Bridge2Health.   The BIC is a premier gathering of leading investors and biotech companies, each offering innovative technology and specialized expertise.    Our participation in this event reflects our ongoing commitment to Belgian entrepreneurs. We have already invested in a number of innovative companies in Belgium, including AstriVax, MRM Health, ProDigest, Amyl Therapeutics and Biobest.   Our mission? To continue supporting innovation and investing in the future of healthcare in Belgium.   #BioInvestmentConvention #Investissement #Innovation #healthcare #Investment #venturecapital